全球腫瘤影像人工智慧市場

腫瘤學領域是醫學影像人工智慧應用最活躍的試驗領域之一，也是人工智慧開始嶄露頭角的領域。從乳癌和肺癌篩檢計畫、複雜的CT/MRI分期、基於PET的治療診斷到放射治療計劃，臨床醫生正面臨更快、更一致、更量化的影像決策挑戰。

本報告量化並闡釋了這項轉變。 我們分析了2023年至2032年全球腫瘤影像人工智慧市場，並採用以下領域的統一細分：

• 依影像方式： CT、X光/DR（含DBT）、MRI、PET/核子醫學、超音波
• 腫瘤部位： 乳癌、肺癌/胸癌、攝護腺癌、大腸癌、肝癌、神經腫瘤、其他
• 臨床應用/治療路徑階段： 從篩檢和風險評估到治療計劃和療效評估
• 收入來源/購買者類型： 硬體附件、軟體、服務、雲端/PPU（癌症中心、IDN/AMC、社區醫療、遠距放射學）

除了定量分析外，本報告還應用了Markintel的綜合框架（M3、ARC-Index、本報告運用 GTM 增長成熟度模型和新開發的升級與包裝階梯模型，展示了人工智能軟體供應商、影像設備製造商、放射治療計劃提供商、人工智能平台、遠程放射學網絡以及製藥公司/CRO 如何將盈利機遇為綜合業務的業務。

本報告的目的不僅在於描述市場，更在於為管理層提供 "洞察到行動" 的行動指南：它明確了腫瘤影像人工智慧真正可以拓展的領域、能夠創造價值的集群，以及未來三到五年內最重要的證據、包裝和合作夥伴關係。

市場概覽

腫瘤影像人工智慧已從實驗性試驗階段發展成為快速擴張的市場。本報告預測，2023 年至 2032 年間，全球市場規模將成長十倍以上，複合年增長率 (CAGR) 約為 30%。儘管北美仍將是最大的收入來源，但亞太地區是成長最快的地區，其成長速度已超過歐洲，這主要得益於各國開展的乳癌和肺癌篩檢計畫、本土原始設備製造商 (OEM) 的發展以及雲端優先技術的加速普及。歐洲仍然是強勁的第二大成長引擎，其普及主要由醫療器材法規 (MDR)、衛生技術評估 (HTA) 和國家篩檢策略推動。

大部分支出集中在 CT、X 光/數位乳房斷層合成 (DBT) 和 MRI 腫瘤工作流程上，而 PET/核醫和超音波則構成了與診斷、定量和介入性腫瘤學相關的較小但高附加價值的細分市場。價值來源也在治療路徑中改變。雖然檢測和診斷仍然是基礎，但越來越多的支出正轉向篩檢、治療計劃和治療反應評估，病灶水平分割、劑量測定和結構化報告已成為現代癌症治療方案的必要要求。 本報告按地區/國家、影像方式、腫瘤部位、臨床應用、治療路徑階段、收入來源和最終用戶場景（癌症中心、IDN/AMC、社區健康中心和遠距放射學）對腫瘤影像領域的人工智慧進行了量化分析。報告訂閱用戶可獲取詳細數據，而公開摘要旨在提供指導。

本報告的主要內容：

• 全球市場規模及預測（2023-2032）－分析了截至2032年的腫瘤影像人工智慧市場現況、成長前景、情境分析以及未來十年的關鍵轉折點。
• 詳細價值池細分 - 根據影像方式、腫瘤部位、臨床應用、治療路徑階段、收入來源和最終用戶環境（癌症中心、IDN/AMC、社區醫院、影像中心和遠距放射學）進行分析，並與 Markintel™ AI-in-Imaging 分類系統保持一致。
• 區域和國家視角 - 對北美、歐洲、亞太地區、拉丁美洲以及中東和非洲進行詳細分析，包括對重點和快速增長國家、篩檢計劃以及當地監管和報銷趨勢的評論。
• 腫瘤治療路徑的臨床和技術趨勢本節描述了 AI 的應用案例，從乳癌和肺癌篩檢到 CT/MR 分期、放射治療計劃、PET 治療診斷和縱向反應評估，並將其映射到篩檢、診斷、分期、計劃、反應評估和隨訪階段。
• 監管、報銷和證據環境 (ARC) 對關鍵應用案例（例如，DBT AI、肺部 CT、自適應放射治療、PET 反應評估和放射組學）的審批、報銷和臨床療效進行評估。包括腫瘤影像領域中 AI 可行領域與仍處於試驗階段領域的比較。
• 按集群劃分的競爭格局 分析六個關鍵競爭集群：AI 軟體、影像設備製造商、放射治療/治療計劃系統供應商、AI 平台和雲端、醫療服務提供者和遠距放射學，以及影像 - 製藥/CRO 和臨床試驗。介紹成長和成熟度市場定位，以及對公司的定性分析。
• 市場推廣和產品組合策略 - Markintel 針對每個集群（基礎版/高級版/精英版）的升級和產品組合方案、推薦的商業和定價規則、通路和合作夥伴策略，以及對附加率提升和套件銷售的影響。
• 策略意義與情境分析 - 深入分析人工智慧在腫瘤影像領域如何成為“工作流程的必要基礎”，亞太地區快速成長對全球競爭的影響，以及未來 3-5 年董事會、產品負責人和投資者的優先事項。

目標公司：

這份名單比較均衡，涵蓋了腫瘤分析中提到的AI軟體專家、設備OEM廠商、放射治療設備供應商、平台營運商、醫療服務提供者/遠距放射治療網路以及影像製藥公司/iCRO。

關鍵統計
地理覆蓋範圍：	北美（美國、加拿大） 歐洲（德國、法國、英國、義大利、歐洲其他地區） 亞太地區（中國、日本、印度、歐洲其他地區） 拉丁美洲 中東和非洲
市場區隔：	依影像模式（CT、X光/DR、MRI、PET/核子醫學、超音波） 依地區（地理覆蓋範圍見上文） 依腫瘤部位（乳癌、肺/胸癌、攝護腺癌、大腸癌、肝癌、神經腫瘤、婦科腫瘤、頭頸部腫瘤、其他） 依臨床應用（檢測/分診、影像分析/定量、報告/自然語言處理、重建/劑量、工作流程調整） 依診療路徑階段（篩檢、診斷、分期、治療計畫（放射治療）、療效評估、追蹤） 依最終使用者機構（癌症中心、IDN/AMC、社區醫院、影像診斷中心、遠距放射學） 依收入來源（硬體升級、軟體授權、服務、雲端/隨選付費） 透過人工智慧技術（偵測、分割/量化、放射組學、自然語言處理/語言學習管理、治理）
主要目標主題：	全球市場規模及預測（2023-2032） 詳細的價值池細分 區域與國家視角 腫瘤學臨床與技術趨勢 監管、報銷和證據環境 (ARC) 按集群劃分的競爭格局 上市與包裝策略 戰略意義與情景
研究方法：	Markintel Horizo​​n 研究計畫 - 醫學影像與人工智慧

表格目錄

第一部分 - 摘要整理

為何此市場至關重要 - 25 秒速覽

全球經濟成長概況 (2023-2032)

資金流向何方？

全球市場驅動因素與限制因素

• 主要驅動因素
• 結構性限制因素

區域脈搏 - 誰會引領，誰會加速？

• 北美
• 亞太
• 歐洲
• 拉丁美洲與中東/非洲

五大策略要點

依模式、應用、途徑劃分的結構性變化最終用途

競爭架構與供應商群集

三年關鍵績效指標展望（2025-2027）及董事會層級行動

• 三年關鍵績效指標展望
• 未來12個月的供應商舉措

第二部分 - 研究方法

關於本報告

範圍和細分 - 我們衡量的是什麼？

• 細分軸

雙鏡頭架構 - 資料建構方式

自上而下的市場漏斗 - 腫瘤領域的錨定

由下而上的附加率流程 - 如何腫瘤收入實際發生

證據可靠性 - 輸入權重和品質檢查

框架堆疊 - 數字如何轉換為行動

目標公司、市場進入成長成熟度與競爭資料集

• 目標公司和聚類
• 市場進入成長與成熟度象限
• 競爭資料集表
• 證據可靠性

升級打包階梯

• 意義
• 預設商業規則

基於聚類的競爭架構與市場區隔橋接

• 聚類（角色）
• 全球聚類<->細分市場橋接

品質保證、限制和場景處理

第三部分 - 策略分析與架構

人工智慧軟體集群

• Markintel M3 - 市場動能矩陣（主要人工智慧軟體細分市場）
  • 如何解讀此矩陣
• Markintel ARC 框架 - 以人工智慧軟體視角解決腫瘤應用案例
  • Markintel ARC 網格 - 人工智慧軟體（腫瘤影像中的人工智慧）
  • 如何解讀此圖表
  • 按細分市場劃分的 ARC 指數 - 人工智慧軟體（腫瘤影像中的人工智慧）
  • ARC - 升級階梯映射 - 人工智慧軟體
  • 建議（人工智慧軟體供應商）
• Markintel 市場拓展成長成熟度矩陣 - 人工智慧軟體供應商（腫瘤影像人工智慧）
  • 如何解讀此矩陣
  • 競爭資料集 - 人工智慧軟體 - 腫瘤影像人工智慧
  • 公司記分板 - 人工智慧軟體 - 腫瘤影像人工智慧
  • 人工智慧軟體 - 市場區隔橋樑
• Markintel 升級與軟體套件階梯 - 人工智慧軟體（腫瘤影像人工智慧）
  • 目標
  • 升級階梯結構 - 人工智慧軟體（腫瘤）軟體包
  • 目標客戶和軟體包配置 - 人工智慧軟體 - 腫瘤升級和軟體包階梯
  • 推薦業務規則 - 人工智慧軟體（腫瘤）
• 公司聚焦 - 人工智慧軟體集群
  • Aidoc
  • AIQ Solutions
  • Koios醫療
  • Lunit
  • Median Technologies
  • Quib​​im
  • QView Medical
  • RadNet/DeepHealth
  • Riverain Technologies
  • ScreenPoint Medical (Transpara)
  • Therapixel (MammoScreen) Vara

影像OEM群聚（腫瘤附加組件和AI套件）

• Markintel M3 - 市場動量矩陣（主要影像OEM細分市場）
  • 如何解讀此矩陣
• Markintel ARC框架 - OEM賦能的腫瘤影像AI用例
  • 主要腫瘤OEM細分市場
  • ARC網格 - 影像OEM
  • 如何解讀此圖表
  • ARC表格 - 影像OEM （腫瘤學）
• Markintel GTM 成長成熟度矩陣 - 影像 OEM（腫瘤影像 AI）
  • 競爭資料集 - 影像 OEM - 腫瘤影像 AI
  • 如何解讀此矩陣
  • 影像 OEM 競爭記分板 - 腫瘤影像中的 AI
  • 影像 OEM 群集 - 腫瘤影像 AI 市場細分橋
• 升級與包裝階梯 - 影像 OEM 鏡頭（腫瘤影像 AI）
  • 目標
  • 階梯結構 - OEM 腫瘤包裝
  • 影像 OEM - 腫瘤 AI 升級和包裝階梯 - 目標客戶和包裝配置
  • 建議的商業規則 - OEM 腫瘤集群
• 特色公司 - 影像 OEM（腫瘤附件和 AI）套房）
  • 佳能醫療
  • 富士軟片醫療
  • 通用電氣醫療
  • 豪洛捷醫療
  • 飛利浦醫療
  • 三星醫療
  • 西門子醫療
  • 聯影醫療

放射治療/腫瘤規劃群聚（自動輪廓、自適應、劑量/反應）

• 摘要整理
• Markintel M3 - 主要細分市場市場動能矩陣（放射治療/腫瘤規劃視角）
  • 目錄（放射治療/腫瘤規劃）
• Markintel ARC框架腫瘤應用案例（放射治療/腫瘤規劃視角）
  • ARC網格 - 放射治療/腫瘤規劃
  • ARC表格 - 放射治療/腫瘤規劃
  • 放射治療建議
• Markintel GTM 成長成熟度矩陣 - 放射治療與腫瘤規劃供應商（腫瘤影像人工智慧）
  • 競爭格局
  • 放射治療/腫瘤規劃 - 市場區隔橋樑
• Markintel 升級與軟體包階梯 - 放射治療/腫瘤規劃
  • 目標
  • 階梯結構 - 放射治療/腫瘤規劃軟體包
  • 放射治療/腫瘤規劃集群 - 腫瘤人工智慧升級和軟體包階梯 - 目標客戶和軟體包配置
  • 建議的商業規則 - 放射治療/腫瘤規劃
• 公司聚焦 - 放射治療/腫瘤規劃
  • Accuray
  • Brainlab
  • Elekta
  • Limbus AI
  • MIM Software
  • Mirada醫療
  • MVision AI
  • RaySearch Laboratories
  • Varian (Siemens)

AI 平台與雲端集群（中立平台、編排、市場）

• 摘要整理
• Markintel M3 - 市場動能矩陣（AI 平台和雲端的主要細分市場）
  • 目錄（AI 平台和雲端）
• Markintel ARC 框架 - AI 平台和雲端解決的腫瘤應用案例
  • ARC 網格 - AI 平台和雲
  • ARC 表格 - AI 平台和雲
• Markintel GTM 成長成熟度矩陣 - AI 平台和雲端提供者（AI 在腫瘤成像中的應用）
  • 競爭格局
  • AI 平台與雲端 - 市場區隔橋樑
• 升級和套餐階梯 - AI 平台和雲端（腫瘤學）
  • 目標
  • 階梯結構 - 平台和雲端套餐
  • AI 平台和雲端 - 腫瘤學升級和套餐階梯 - 腫瘤影像人工智慧
  • 建議的預設商業規則 - 平台和雲
• 公司聚焦 - AI 平台和雲
  • CARPL.ai
  • deepc (deepcOS)
  • Ferrum Health
  • Incepto
  • Nuance 精準影像網路 (PIN)
  • Tempus (Arterys)

提供者和遠距放射學集群（AI 輔助服務）

• 摘要整理
• Markintel M3 - 市場動能矩陣（供應商和遠距放射學主要細分領域）
  • 描述（供應商和遠距放射學）
• Markintel ARC Frame

Oncology is where medical imaging AI is being tested most aggressively-and where it is starting to stick. Breast and lung screening programs, complex CT/MRI staging, PET-based theranostics, and RT planning are all pushing clinicians toward faster, more consistent, more quantitative imaging decisions.

This Markintel(TM) Horizon report quantifies and explains that shift. It analyzes the World Market for Oncology Imaging AI from 2023 to 2032, using a consistent segmentation across:

• Modality: CT, X-ray/DR (incl. DBT), MRI, PET/Nuclear, Ultrasound
• Tumor site: Breast, Lung/Chest, Prostate, Colorectal, Liver, Neuro-oncology, and others
• Clinical application & pathway stage: from Screening & Risk through Treatment Planning and Response
• Revenue stream & buyer type: Hardware attach, Software, Services, Cloud/PPU across Cancer Centers, IDNs/AMCs, Community providers, and Teleradiology

Beyond the numbers, the report applies the full Markintel framework stack-M3, ARC-Index, GTM Growth-Maturity, and the new Upgrade & Package Ladders-to show how AI Software vendors, Imaging OEMs, RT planning providers, AI Platforms, Providers/Telerad networks, and Imaging-Pharma/CROs can convert opportunity into repeatable, profitable business.

The goal is not just to describe the market, but to give executives an insights-to-action playbook: where Oncology Imaging AI is truly ready to scale, which clusters will capture the value, and what evidence, packaging, and partnerships will matter most over the next three to five years.

Market Snapshot

Oncology Imaging AI has moved from experimental pilots to a fast scaling market. The report sizes a global opportunity that expands more than 10x between 2023 and 2032, with a compound annual growth rate in the low 30s. North America remains the largest revenue pool over the horizon, but Asia-Pacific is the fastest growing region, overtaking Europe on momentum as national breast and lung programs, domestic OEMs, and cloud first deployments ramp. Europe stays a strong second engine, with adoption paced by MDR, HTA, and national screening strategies.

Most spend concentrates in CT, X ray/DBT and MRI oncology workflows, with PET/Nuclear and Ultrasound forming smaller but high value niches tied to theranostics, quantification, and interventional oncology. The mix of value pools also shifts along the pathway: Detection & Diagnosis remains foundational, but more spend migrates toward screening, treatment planning, and response assessment, where lesion level segmentation, dosimetry, and structured reporting are becoming mandatory for modern cancer programs.

The report quantifies Oncology Imaging AI across regions and countries, modalities, tumor sites, clinical applications, pathway stages, revenue streams, and end use settings (cancer centers, IDNs/AMCs, community providers, teleradiology). Detailed numbers are reserved for report buyers; the public snapshot is directional by design.

What's Covered:

• Global market sizing & forecast (2023-2032) - total Oncology Imaging AI market today and through 2032, with growth outlook, scenario commentary and key inflection points along the decade.
• Granular segmentation of value pools - analysis by modality, tumor site, clinical application, pathway stage, revenue stream and end-use setting (cancer centers, IDNs/AMCs, community hospitals, imaging centers, teleradiology), aligned with the broader Markintel(TM) AI-in-Imaging taxonomy.
• Regional & country perspectives - detailed views for North America, Europe, Asia-Pacific, Latin America and Middle East & Africa, including commentary on leading and fast-growth countries, screening initiatives, and local regulatory/reimbursement dynamics.
• Clinical & technology trends across the oncology pathway - how AI is being deployed from breast and lung screening through CT/MR staging, RT planning, PET theranostics and longitudinal response assessment, with use-case mapping to Screening, Diagnosis, Staging, Planning, Response and Surveillance stages.
• Regulatory, reimbursement and evidence landscape (ARC) - assessment of Approvals, Reimbursement and Clinical validation by key use case (e.g., DBT AI, CT-lung, adaptive RT, PET response, radiomics), including where Oncology Imaging AI is deployment-ready vs where it remains pilot-only.
• Competitive landscape by cluster - analysis of six major competitive clusters (AI Software, Imaging OEMs, RT/TPS vendors, AI Platforms & Cloud, Providers & Teleradiology, Imaging-Pharma/CRO & Trials), with GTM Growth-Maturity positioning and qualitative company spotlights.
• GTM & packaging strategies - Markintel Upgrade & Package Ladders for each cluster (Foundation / Advanced / Elite), recommended commercial and pricing rules, channel and partnership strategies, and implications for attach-rate expansion and suite-based selling.
• Strategic implications & scenarios - cross-cutting insights on where Oncology Imaging AI is likely to become "workflow-critical infrastructure," how APAC's faster growth changes global competition, and what boards, product leaders and investors should prioritize over the next 3-5 years.

Companies Covered:

The list is cluster balanced-it includes AI software specialists, modality OEMs, RT/TPS vendors, platform players, provider/telerad networks, and imaging pharma/iCROs that feature in the oncology analysis.

KEY STATISTICS
Geographical Coverage:	North America (US, Canada) Europe (Germany, France, UK, Italy, Rest of Europe) Asia Pacific (China, Japan, India, Rest of Asia-Pacific) Latin America Middle East & Africa
Market Segmentation:	By Modality (CT, X-ray/DR. MRI, PET/Nuclear, Ultrasound) By Geographic Region (see above for Geographic Coverage) By Tumor Site (Breast, Lung/Chest, Prostate, Colorectal, Liver, Neuro-Onc, Gyn, H&N, Other) By Clinical Application (Detection/Triage, Seg/Quant, Reporting/NLP, Recon/Dose, Workflow Orchestration) By Pathway Stage (Screening, Diagnosis, Staging, Planning (RT), Therapy Response, Surveillance) By End-Use Org (Cancer Centers, IDNs/AMCs, Community Hospitals, Imaging Centers, Teleradiology) By Revenue Stream (Hardware Uplift, Software Licenses, Services, Cloud/PPU) By AI Technology (Detection, Seg/Quant, Radiomics, NLP/LLM, Governance)
Key Topics Covered:	Global market sizing & forecast (2023-2032) Granular segmentation of value pools Regional & country perspectives Clinical & technology trends across the oncology pathway Regulatory, reimbursement and evidence landscape (ARC) Competitive landscape by cluster GTM & packaging strategies Strategic implications & scenarios
Methodology:	Markintel Horizon Research Program - Medical Imaging & AI

TABLE OF CONTENTS

SECTION 1 - EXECUTIVE SUMMARY

Why This Market Matters - The 25-Second Read

Global Growth at A Glance (2023-2032)

Where Along the Pathway the Money Is Moving

Global Market Drivers & Restraints

• Key Growth Drivers
• Structural Restraints

Regional Pulse - Who Leads, Who Accelerates

• North America
• Asia-Pacific
• Europe
• LATAM & MEA

Five Strategy Headlines to Internalize

Structural Shifts by Modality, Application, Pathway, And End-Use

Competitive Architecture and Vendor Clusters

Three-Year KPI Outlook (2025-2027) & Board-Level Actions

• Three-Year KPI Outlook
• Actions For Vendors Over the Next 12 Months

SECTION 2 - RESEARCH METHODOLOGY

About This Report

Scope & Segmentation - What is Being Measured

• Segmentation Axes

Dual-Lens Architecture - How Numbers Are Built

Top-Down Market Funnel - Anchoring the Oncology Slice

Bottom-Up Attach-Rate Flow - How Oncology Revenue Actually Accrues

Evidence Confidence - How We Weight and Quality-Check Inputs

Framework Stack - Why the Numbers Are Actionable

Company Coverage, GTM Growth-Maturity & Competitive Datasets

• Company Universe And Clustering
• GTM Growth-Maturity Quadrants
• Competitive Dataset Tables
• Evidence Confidence

Upgrade & Package Ladders

• Definition
• Default Commercial Rules

Cluster-Based Competitive Architecture & Market Segment Bridging

• Clusters (Roles)
• Global Cluster<->Segment Bridge

Quality Assurance, Limitations, And Scenario Handling

SECTION 3 - STRATEGIC ANALYSIS & FRAMEWORKS

AI SOFTWARE CLUSTER

• Markintel M3 - Market Momentum Matrix (AI Software Key Sub-Segments)
  • How to Read This Matrix
• Markintel ARC Framework - Oncology Use Cases Addressable by AI Software Lens
  • Markintel ARC Grid - AI Software (Oncology Imaging AI)
  • How to Read This Exhibit
  • ARC-Index by Segment - AI Software (Oncology Imaging AI)
  • ARC -> Upgrade Ladder Mapping - AI Software
  • Recommendations (AI Software Vendors)
• Markintel GTM Growth-Maturity Matrix - AI Software Vendors (Oncology Imaging AI)
  • How To Read This Matrix
  • Competitive Dataset - AI Software - Oncology Imaging AI
  • Company Scoreboard - AI Software - Oncology Imaging AI
  • AI Software - Market Segmentation Bridge
• Markintel Upgrade & Package Ladder - AI Software (Oncology Imaging AI)
  • Objective
  • Upgrade Ladder Structure - AI Software (Oncology) Packages
  • Target Customers & Package Composition - AI Software - Oncology Upgrade & Package Ladder
  • Recommended Commercial Rules - AI Software (Oncology)
• Company Spotlights - AI Software Cluster
  • Aidoc
  • AIQ Solutions
  • Koios Medical
  • Lunit
  • Median Technologies
  • Quibim
  • QView Medical
  • RadNet / DeepHealth
  • Riverain Technologies
  • ScreenPoint Medical (Transpara)
  • Therapixel (MammoScreen)
  • Vara

IMAGING OEMs CLUSTER (ONCOLOGY ATTACH & AI SUITES)

• Markintel M3 - Market Momentum Matrix (Imaging OEMs Key Sub-Segments)
  • How to Read This Matrix
• Markintel ARC Framework - Oncology Imaging AI Use Cases Addressable by OEMs
  • Key OEM Oncology Segments
  • ARC Grid - Imaging OEMs
  • How to Read This Exhibit
  • ARC Table - Imaging OEMs (Oncology)
• Markintel GTM Growth-Maturity Matrix - Imaging OEMs (Oncology Imaging AI)
  • Competitive Dataset - Imaging OEMS - Oncology Imaging AI
  • How to Read this Matrix
  • Imaging OEMs Competitive Scoreboard - Oncology Imaging AI
  • Imaging OEMs Cluster - Oncology Imaging AI Market Segmentation Bridge
• Upgrade & Package Ladder - Imaging OEMs Lens (Oncology Imaging AI)
  • Objective
  • Ladder Structure - OEM Oncology Packages
  • Imaging OEMs - Oncology AI Upgrade & Package Ladder - Target Customers & Package Composition
  • Recommended Commercial Rules - OEM Oncology Cluster
• Company Spotlights - Imaging OEMs (Oncology Attach & AI Suites)
  • Canon Medical
  • Fujifilm Healthcare
  • GE HealthCare
  • Hologic
  • Philips Healthcare
  • Samsung Healthcare
  • Siemens Healthineers
  • United Imaging

RT / ONCOLOGY PLANNING CLUSTER (AUTO-CONTOUR, ADAPTIVE, DOSE/RESPONSE)

• Executive Summary
• Markintel M3 - Market Momentum Matrix of Key Subsegments (RT/Oncology Planning Lens)
  • What it Says (RT / Oncology Planning)
• Markintel ARC-Framework by Oncology Use Case (RT/Oncology Planning Lens)
  • ARC Grid - RT/Oncology Planning
  • ARC Table - RT / Oncology Planning
  • RT Recommendations
• Markintel GTM Growth-Maturity Matrix -- RT & Oncology Planning Vendors (Oncology Imaging AI)
  • Competitor Scoreboard
  • RT / Oncology Planning - Market Segmentation Bridge
• Markintel Upgrade & Package Ladder - RT / Oncology Planning
  • Objective
  • Ladder structure - RT / Oncology Planning packages
  • RT/Oncology Planning Cluster - Oncology AI Upgrade & Package Ladder - Target Customers & Package Composition
  • Recommended Commercial Rules - RT / Oncology Planning
• Company Spotlights - RT / Oncology Planning
  • Accuray
  • Brainlab
  • Elekta
  • Limbus AI
  • MIM Software
  • Mirada Medical
  • MVision AI
  • RaySearch Laboratories
  • Varian (Siemens)

AI PLATFORMS & CLOUD CLUSTER (NEUTRAL PLATFORMS, ORCHESTRATION, MARKETPLACES)

• Executive Summary
• Markintel M3 - Market Momentum Matrix (AI Platforms & Cloud Key Sub-Segments)
  • What it Says (AI Platforms & Cloud)
• Markintel ARC Framework - Oncology Use Cases Addressable by AI Platforms & Cloud
  • ARC Grid - AI Platforms & Cloud
  • ARC Table - AI Platforms & Cloud
• Markintel GTM Growth-Maturity Matrix - AI Platforms & Cloud Providers (Oncology Imaging AI)
  • Competitor Scoreboard
  • AI Platforms & Cloud - Market Segmentation Bridge
• Upgrade & Package Ladder - AI Platforms & Cloud (Oncology)
  • Objective
  • Ladder Structure - Platform & Cloud packages
  • AI Platforms & Cloud - Oncology Upgrade & Package Ladder - Oncology Imaging AI
  • Recommended Default commercial Rules - Platforms & Cloud
• Company Spotlights - AI Platforms & Cloud
  • CARPL.ai
  • deepc (deepcOS)
  • Ferrum Health
  • Incepto
  • Nuance Precision Imaging Network (PIN)
  • Tempus (Arterys)

PROVIDERS & TELERADIOLOGY CLUSTER (AI-ASSISTED SERVICES)

• Executive Summary
• Markintel M3 - Market Momentum Matrix (Providers & Teleradiology Key Subsegments)
  • What it Says (Providers & Telerad)
• Markintel ARC Framework - Oncology Use Cases Addressable by Providers & Teleradiology
  • ARC Grid - Providers & Teleradiology
  • ARC Table - Providers & Teleradiology
• GTM Growth-Maturity Matrix - Providers & Teleradiology Networks (Oncology Imaging AI)
  • Competitive Dataset - Services Rails, Governance, Oncology Footprint
  • Competitive Scoreboard
  • Providers & Teleradiology - Market Segmentation Bridge
• Markintel Upgrade & Package Ladder - Providers & Teleradiology (Oncology)
  • Objective
  • Ladder Structure - Oncology Service Packages
  • Providers & Teleradiology - Oncology Upgrade & Package Ladder - Target Customers & Package Composition
  • Recommended Default Commercial Rules - Providers & Teleradiology
• Company Spotlights - Providers & Teleradiology (AI-Assisted Services)
  • 5C Network
  • Everlight Radiology
  • DocPanel
  • RadNet / DeepHealth
  • Teleradiology Solutions
  • Unilabs / Telemedicine Clinic (TMC)
  • vRad

IMAGING-PHARMA / CRO & TRIALS CLUSTER (RADIOMICS, RESPONSE, THERANOSTICS)

• Executive Summary
• Markintel M3 - Market Momentum Matrix (Imaging-Pharma / CRO & Trials Key Sub-Segments)
  • M3 Table - Imaging-Pharma / CRO & Trials
• Markintel ARC Framework - Oncology Imaging AI Use Cases Addressable by Imaging-Pharma / CRO & Trials
  • ARC Grid - Imaging-Pharma / CRO & Trials
  • ARC Table - Imaging-Pharma / CRO & Trials
• Markintel GTM Growth-Maturity Matrix - Imaging-Pharma & CROs (Oncology Imaging AI)
  • Competitive Dataset - endpoint standardization & clinic bridge
  • Competitor Scoreboard
  • Imaging-Pharma / CRO & Trials - Market Segmentation Bridge
• Upgrade & Package Ladder - Imaging-Pharma / CRO & Trials
  • Objective
  • Ladder Structure - Imaging-Pharma / CRO & Trials
  • Imaging-Pharma / CRO & Trials - Upgrade & Package Ladder - Target Customers and Package Composition
  • Recommended Default Commercial Rules - Imaging-Pharma / CRO & Trials
• Company Spotlights - Imaging-Pharma / CRO & Trials (Radiomics, Response, Theranostics)
  • AIQ Solutions
  • Bracco
  • Guerbet
  • Lantheus / EXINI (aPROMISE / PYLARIFY AI)
  • Median Technologies
  • Quibim

SECTION 4 - WORLD MARKET FOR ONCOLOGY IMAGING AI

WORLD MARKET OVERVIEW

• Oncology Imaging AI: From Niche App to Enterprise Platform
  • Why Adoption is Accelerating
• Regional Growth Snapshot (2023 -> 2032)
• Strategic Implications for Vendors
• Market Momentum & Outlook

WORLD MARKET FORECAST BY REGION (2023-2032)

WORLD MARKET BY COUNTRY x END-USE ORG

• Estimate by Country x End-Use (USD Mill, 2023)
• Forecast by Country x End-Use (2032)
• Highlights (2032 Country Pattern vs World Mix)
• What's Shifting vs 2023 (Directional)
• Top Growth Cells (US$ M Lift, 2023->2032)
• What This Means (Commercial Playbook)
• Signals to Watch

WORLD MARKET BY MODALITY

• Highlights
• World Market by Modality (2023-32)
  • Implications
• Market Math & Diffusion Pattern
  • 2032 Mix and Key Growth Lenses
  • Share Shift and Dollar Lift (2023 -> 2032)
• Competitive Landscape - by Modality
• Modality Deep-Dives (Oncology-specific)
  • CT
  • X-ray/DR (incl. Mammography)
  • MRI
  • PET/Nuclear
  • Ultrasound
• Strategic Takeaways for Vendors (Oncology-specific)
• Signals to Watch (2025-2027)

WORLD MARKET BY CLINICAL APPLICATION

• Highlights
• World Market by Clinical Application (2023-32)
• What's Shifting
• Key Growth Lenses by Application
• Who Contributes the Growth (2023->2032 lift)
• What This Means
• Competitive Landscape - by Clinical Application
• Deep Dives by Clinical Application
  • Detection & Diagnosis
  • Quantification & Analytics
  • Workflow & Orchestration
  • Reporting & Communication
  • Image Reconstruction & Acquisition
• Strategic Takeaways for Vendors
• Signals to Watch (2025-2027)

WORLD MARKET BY TUMOR SITE

• Highlights
• What's Shifting (Mix Dynamics)
• World Market by Tumor Site (2023-32)
• Growth Lenses - by Tumor Site
• What This Means
• What Shifts Through 2032
• Commercial Takeaways
• Competitive Landscape - by Tumor Site
• Deep Dives by Tumor Site
  • Breast
  • Lung/Chest
  • Prostate
  • Colorectal
  • Liver
  • Neuro-Oncology
  • Gynecologic
  • Head & Neck
  • Other (Rare)
• Strategic Takeaways
• Signals to Watch (2025-2027)

WORLD MARKET BY REVENUE STREAM

• Highlights
• What's Shifting
• World Market by Revenue Stream (2023-32)
• Growth Lenses - by Revenue Stream
• Who Contributes the Growth (2023->2032 Dollar Lift)
• What This Means
• Deep Dives by Revenue Stream
  • Hardware
  • Software
  • Service
  • Cloud/PPU
• Competitive Landscape - by Revenue Stream
• Signals to Watch (2025-2027)

WORLD MARKET BY END-USE ORGANIZATION TYPE

• Highlights
• What's Shifting
• World Market by End-Use Organization (2023-32)
• Growth Lenses by End-use
• Who Contributes the Growth (2023->2032 Dollar Lift)
• What this Means
• Deep Dives
  • Academic/IDNs
  • Comprehensive Cancer Centers
  • Community Hospitals & Imaging Centers
  • Teleradiology Providers
• Competitive Landscape - by End-Use
• Signals to Watch (2025-2027)

WORLD MARKET BY AI TECHNOLOGY

• Highlights
• What's Shifting
• World Market by AI Technology (2023-32)
• Growth Lenses - by AI Technology
• Who Contributes the Growth (2023->2032 Dollar Lift)
• What This Means
• Deep Dives by AI Technology (Oncology Lens)
• Competitive Landscape - by AI Technology
• Signals to Watch (2025-2027)

WORLD MARKET BY PATHWAY STAGE

• Highlights
• What's Shifting
• World Market by Pathway Stage (2023-32)
• Growth Lenses - by Pathway Stage
• Who Contributes the Growth (2023->2032 Dollar Lift)
• What This Means
• Competitive Landscape - by Pathway Stage
• Signals to Watch (2025-2027)

REGIONAL MIX & MOMENTUM - WORLD ONCOLOGY IMAGING AI

• Executive Takeaways
• Marke by Region x Modality
  • World Market by Region x Modality - 2023
  • World Market by Region x Modality - 2032
  • What's Shifting (Mix, 2032 Over/Under-index)
  • Who Contributes the Growth (2023->2032 Lift)
  • What This Means
• Market by Region x Revenue Stream
  • World Market by Region x Revenue Stream - 2023
  • World Market by Region x Revenue Stream - 2032
  • What's Shifting (Mix, 2032 Over/Under Index)
  • Who Contributes the Growth
  • What This Means
• Market by Region x Clinical Application
  • World Market by Region x Clinical Application - 2023
  • World Market by Region x Clinical Application - 2032
  • What's Shifting (Mix, 2032 Over/Under Index)
  • Who Contributes the Growth
  • What this Means
  • Competitive Snapshots (Illustrative)

DISEASE-DRIVEN DEMAND MAP - WORLD ONCOLOGY IMAGING AI

• Executive Takeaways
• Tumor Site x Modality
  • World Market by Tumor Site x Modality - 2023
  • World Market by Tumor Site x Modality - 2032
  • What's Shifting (2032 Mix vs Global)
  • Who Contributes the Growth (2023->2032 Dollar Lift)
  • What This Means
• Tumor Site x Clinical Application
  • World Market by Tumor Site x Clinical Application - 2023
  • What's Shifting (2032 Mix vs Global)
  • World Market by Tumor Site x Clinical Application - 2032
  • Who Contributes the Growth (2023->2032 Dollar Lift)
  • What this means
• Tumor Site x Revenue Stream
  • World Market by Tumor Site x Revenue Stream - 2023
  • World Market by Tumor Site x Revenue Stream - 2032
  • What's Shifting (2032 mix vs global)
  • Who Contributes the Growth (2023->2032 Dollar lift)
  • What This Means
• Competitive Snapshot (Illustrative, Oncology-focused)
• Signals to Watch

WORKFLOW ECONOMICS - WORLD ONCOLOGY IMAGING AI

• Modality x Revenue Stream
  • World Market by Modality x Revenue Stream - 2023
  • World Market by Modality x Revenue Stream - 20232
  • Highlights
  • What's Shifting (Mix & Over/Under-Index)
  • Who Contributes the Growth (2023->2032 Dollar Lift)
  • What This Means (Commercial Playbook)
  • Competitive Lens (Illustrative)
• Clinical Application x Revenue Stream
  • Highlights (2032 Pattern)
  • World Market by Clinical Application x Revenue Stream - 2023
  • World Market by Clinical Application x Revenue Stream - 2032
  • What's Shifting (2023 -> 2032)
  • Who Contributes the Growth (US$ M lift, 2023->2032)
  • What This Means (Commercial Playbook by Application)
  • Competitive Lens (Indicative, Non-exhaustive)
  • Pricing Archetypes That Clear Approvals (What Buyers Say "Yes" to)
  • Signals to Watch
  • Risks & Watchouts

PATHWAY STAGE ECONOMICS - WORLD ONCOLOGY IMAGING AI

• Pathway Stage x Revenue Stream
  • Highlights
  • World Market by Pathway Stage x Revenue Stream - 2023
  • World Market by Pathway Stage x Revenue Stream - 2032
  • What's Shifting (Mix vs Global)
  • Who Contributes the Growth (2023 -> 2032 Dollar Lift)
  • What This Means (Commercial Playbook)
  • Competitive Lens (Indicative)
  • Signals to Watch
• Pathway Stage x Modality - Where Each Stage Leans and Why
  • World Market by Pathway Stage x Modality - 2023
  • World Market by Pathway Stage x Modality - 2032
  • Highlights (2032 Pattern vs World Mix)
  • Where the Dollars Moved (2023 -> 2032)
  • Stage-specific Readouts (2032 Shares Inside Each Stage)
  • What This Means (Commercial Takeaways)
  • Competitive Lens (Illustrative, not Exhaustive)
  • Signals to Watch
• Pathway Stage x Clinical Application - How Workloads Drive Spend
  • World Market by Pathway Stage x Clinical Application - 2023
  • World Market by Pathway Stage x Clinical Application - 2032
  • Highlights (2032 Pattern vs World Mix)
  • Where the Dollars Moved (2023 -> 2032)
  • What This Means (Commercial Playbook)
  • Competitive Lens (Indicative)
  • Signals to Watch
• Pathway Stage x End-use - Who Buys What, and Where Growth Concentrates
  • World Context (2032 End-use Mix)
  • World Market by Pathway Stage x End-use - 2023
  • World Market by Pathway Stage x End-use - 2032
  • Highlights (2032 Pattern vs Global Mix)
  • Who Contributes the Growth (US$ M lift 2023->2032)
  • What This Means (Commercial Playbook by Stage)
  • Competitive Lens (Indicative, Non-exhaustive)
  • Signals to Watch
• Pathway Stage x AI Technology - How Capability Mix Shifts Across the Cancer Pathway
  • World Tech Mix
  • World Market for Pathway Stage x AI Technology - 2023
  • World Market for Pathway Stage x AI Technology - 2032
  • Highlights (2032 Pattern vs Global Mix)
  • Where the Dollars Moved (2023 -> 2032)
  • What This Means (Commercial Playbook)
  • Competitive Lens (indicative)
  • Signals to Watch

SECTION 5 - NORTH AMERICA

North America - Market Overview & Dynamics

• North America - Executive Summary
• Market Size - (Country Roll-up)
  • What's Moving the Market
  • Key Differences to Plan Around
  • Structure of Spend by Revenue Stream (NA)
  • End-Use Organizations (NA)
  • AI Technology (NA)
  • Pathway Stage (NA)
  • Strategic Implications (North America)
  • What to Watch (Leading Indicators)

Market Analysis & Estimates + Forecasts

• North America - Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • North America - Market Math & Diffusion (Modality)
  • What's Driving North America (Shared Signals)
  • Where the Growth Comes From
  • Buyer & Hosting Posture
  • Commercial Playbook (NA)
  • What's Common Across NA (Region-Level Truths)
  • Key Differences (U.S. vs Canada)
  • Competitive Lens (Indicative, NA-relevant)
  • Regulatory & Reimbursement Scenarios (What to Plan for)
  • Commercial Playbook (NA)
  • Signals to Watch (Leading Indicators)
  • Risks & Mitigations
  • 90-Day Action List
• North America - Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Market Math & Diffusion - North America, Clinical Application
  • Headline Math
  • What's Common Across the Region
  • Where the U.S. and Canada Differ (and How to Win)
  • Who Drives the Growth
  • Pricing & Packaging
  • Competitive Lens (indicative)
  • Signals to Watch ('25-'28)
  • Risk Notes
• North America - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Growth Engines (What's Moving)
  • What's Shifting (Mix and Posture)
  • Buyer & Hosting Posture (Regional Commonalities vs. Differences)
  • Who Drives the Growth (by Tumor)
  • Pricing & Packaging
  • Signals to Watch ('25-'28)
  • Actionable Mix
  • Risks
• North America - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Headline Mix & Lift (US$M, 2023->2032)
  • What's Driving Spend Patterns
  • US vs Canada - Common Rails, Different Motions
  • Regulatory & Reimbursement Cues
  • Packaging & Pricing Posture
  • GTM by Stream
• North America - Market by End-Use Organization Type
  • Forecast by End-Use Organization Type (USD Mill, 2023-32)
  • Headlines
  • Where the Dollars Land by 2032
  • Country Split of the Lift ('23->'32)
  • Implications for Go-to-Market
• North America - Market by AI Technology
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Headlines
  • Where the Dollars Land by 2032 (Share / CAGR / Lift)
  • Mix Shift (2023 -> 2032)
  • Country Split of Dollar-lift ('23->'32)
  • Implications for Go-to-Market
• North America - Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Headlines
  • Where the Dollars Land by 2032 (Share / CAGR / Lift)
  • Mix Shift (2023 -> 2032)
  • Country Split of the Dollar-Lift ('23->'32)
  • Implications for Go-to-Market

SECTION 6 - UNITED STATES

US Market Overview and Dynamics

• Market Size Summary
• What's Driving the U.S. (Demand & Supply)
• Attach, Pricing & Adoption Posture
• Distribution Rails & OEM Effects
• Regulatory, Evidence & Reimbursement Posture (Practical)
• Buyer & Hosting Posture (What U.S. Committees Expect)
• Commercial Playbook (How to Win)
• Risks & Watch-outs
• U.S. Vendor & Channel Snapshot (indicative)
• United States - At-a-Glance
  • Key Numbers (2023->2032)
  • Three Takeaways

US Market Estimates & Forecasts

• US Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (2025->2029)
  • Market Math & Diffusion (United States, Modality)
  • Who Drives the Lift
  • Pricing & Packaging (How to Win)
  • Competitive Lens (Indicative)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-day Playbook (US)
• US Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (2025->2029)
  • Who Drives the Growth ('23->'32 Dollar-lift)
  • Market Math & Diffusion (United States, Clinical Application)
  • Pricing & Packaging - How to Win
  • Competitive Lens (Indicative)
  • Signals to Watch ('25-'28)
  • Risks
• US Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Highlights
  • Incidence & Screening Context (Indicative, US)
  • What's Shifting (2025->2029)
  • Who Drives the Growth ('23->'32 dollar-lift)
  • Market Math & Diffusion (United States, Tumor Site)
  • Pricing & Packaging - How to Win
  • Signals to Watch
• US Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (2025->2029)
  • Who Drives the Growth ('23->'32 dollar-lift)
  • Market Math & Diffusion (United States, Revenue Stream)
  • Pricing & Packaging - How to Win
  • Buyer & Hosting Posture (US Reality)
  • Signals to Watch
  • 90-day Playbook (Practical)
  • Competitive Lens (Indicative)
• US Market by End-Use Organization Type
  • Forecast by End-Use Organization (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (2025->2029)
  • Who Drives the Growth ('23->'32 dollar-lift)
  • Market Math & Diffusion (United States, End-Use Org)
  • Pricing & Packaging - How to Win
  • Buyer & Hosting Posture (US)
  • Signals to Watch
  • 90-day Playbook
• US Market by AI Technology
  • Forecast by AI Technology (2023-32)
  • Highlights
  • What's Shifting (2025->2029)
  • Who Drives the Growth ('23->'32 dollar-lift)
  • Pricing & Packaging - How to Win
  • Market Math & Diffusion (United States, AI Technology)
  • Buyer & Hosting Posture (US)
  • Signals to Watch
  • 90-day Playbook
• US Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (2025->2029)
  • Market Math & Diffusion (United States, Pathway Stage)
  • Who Drives the Growth ('23->'32 dollar-lift)
  • Pricing & Packaging - How to Win
  • Buyer & Hosting Posture
  • Signals to Watch
  • 90-day Playbook

SECTION 7 - CANADA

• Market Overview & Dynamics (2023->2032)
  • Where the Growth is
  • What's Driving Canada
  • Commercial
• Canada - At a Glance
  • Key Numbers
  • 2032 Mix Snapshot (Steady State)
  • Where the Dollars Come From ('23->'32 Lift)
  • Three Takeaways
• Buyer & Hosting Posture (Canada)
• Incidence & Screening (Context Signals)
• Policy & Reimbursement Signals (Canada-specific)
• Provider Landscape Snapshot (indicative, oncology-heavy)
• Packaging & Pricing Realities (Canada)
• Evidence & Regulatory Notes (Canada-relevant)
• Competitive Landscape (Indicative Clusters)

Canada - Market Estimates & Forecasts (Canada)

• Canada - Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (What's Doing the Lifting)
  • Who Contributes the Growth
  • What This Means (Commercial Playbook)
  • Competitive Lens (Indicative Clusters)
  • Signals to Watch
  • Risks & Watch-outs
• Canada - Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Canada, Clinical Application)
  • Who Contributes the Growth
  • What This Means (Commercial Playbook)
  • Packaging & Monetization Matrix (Canada)
  • Competitive Lens (Indicative Clusters)
  • Signals to Watch
  • Risks & Watch-outs
• Canada - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Canada, Tumor Site)
  • Who Contributes the Growth
  • What This Means (Commercial Playbook)
  • Packaging & Monetization Matrix (by Tumor, Canada)
  • Competitive Lens (Indicative)
  • Signals to Watch
  • Risks & Watch-outs
• Canada - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Canada, Revenue Stream)
  • Who Contributes the Growth
  • What This Means (Commercial Playbook)
  • Packaging & Monetization Guardrails (Canada)
  • Competitive Lens (Indicative)
  • Signals to Watch
  • Risks & Watch-outs
• Canada - Market by End-Use Organization Type (2023-32)
  • Forecast by End-Use Organization Type (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Canada, End-Use Orgs)
  • What This Means (Commercial Playbook)
  • Packaging & Monetization Matrix - by Buyer Type (Canada)
  • Signals to Watch
  • Risks & Watch-outs
• Canada - Market by AI Technology (2023-32)
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Canada, AI Technology)
  • Who Contributes the Growth
  • What This Means (Commercial Playbook)
  • Packaging & Monetization Matrix (Canada)
  • Competitive Lens (Indicative)
  • Signals to Watch
  • Risks & Watch-outs
• Canada - Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Canada, Pathway Stages)
  • Who Contributes the Growth
  • What This Means (Commercial Playbook)
  • Packaging & Monetization Matrix (Canada)

SECTION 8 - EUROPE

Market Overview and Dynamics

• Headlines (Scale & Slope)
• What's Changing Around Access & Regulation
  • Reimbursement, Funding & Procurement (Where Money Comes From)
  • Clinical & Operational Proof Points (Confidence to Buy)
  • How the Money Splits
  • Buyer-side Patterns
  • Risks & Watch-outs
  • Go-to-Market Implications (Europe-wide)
  • 12-month Operating Plan (Minimum Viable)

Market Estimates & Forecasts

• Europe - Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Headlines
  • Where the Dollars Land by 2032 (Europe Totals; rounded)
  • Source: Marketstrat Estimates & Forecast Model
  • Country Split of the Lift ('23->'32)
  • Growth vs. Scale (what the Bubble shows)
  • Mix-shift (2023 -> 2032)
  • Implications for Go-to-Market
• Europe - Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Europe Totals by Clinical Application
  • Deeper Dive
  • Who Drives Each Application? (2032 Revenue Split Within Each Application)
  • Interpretation
  • Commercial Implications
• Europe - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Headlines
  • Regional Synthesis
  • Europe Totals by Tumor Site (Rolled-Up; Rounded)
  • Who Drives Each Site? (2032 revenue split within site)
  • Commercial Implications
• Europe - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Headlines
  • Structure of Spend (rolled-up, rounded)
  • What This Means
  • Commercial Moves
• Europe - Market by End-Use Organization Type
  • Forecast by End-Use Org Type (USD Mill, 2023-32)
  • Headlines
  • Regional Synthesis
  • Europe Totals by End-Use Org (Rolled-Up; Rounded)
  • Commercial Implications (Europe)
• Europe - Market by AI Technology
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Headlines (Europe - AI Technology)
  • Where the Growth Comes From (2023->2032 Lift)
  • Commercial Implications
• Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Headlines
  • Regional Synthesis
  • Europe Pathway Stage Totals
  • Commercial Implications

SECTION 9 - GERMANY

Germany - Market Overview and Analysis

• Headlines
• What's Driving Germany (Why This Curve Is Steep)
• "So What" - GTM & Packaging for Germany
• Germany - At a Glance
  • Key Numbers
  • 2032 Mix Snapshot (steady state)
  • Where the Dollars Come From ('23->'32 Lift)
  • Three Takeaways
• Buyer & Hosting Posture (Germany)
• Incidence & Screening - Context Signals
• What To Watch (Germany)

Germany - Market Estimates & Forecasts

• Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Germany, Modality)
  • Who Contributes the Growth
  • Signals to Watch (Germany-Specific)
  • What This Means (Commercial Playbook)
  • Risks & Watch-outs
• Germany - Market Size by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Germany, Clinical Applications)
  • Who Contributes the Growth
  • What This Means (Commercial Playbook)
  • Competitive Lens (Indicative)
  • Signals to Watch (Germany)
  • Risks & Watch-outs
• Germany - Market by Tumor Site
  • Highlights
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • What's Shifting
  • What This Means (Commercial Playbook)
  • Market Math & Diffusion (Germany, Tumor Site)
• Germany - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market-Math & Diffusion (Germany, Revenue Streams)
  • Who Contributes the Growth
  • What This Means (Commercial Playbook)
  • Packaging & Monetization Guardrails (Germany)
  • Signals to Watch
  • Risks & Watch-outs
• Germany - Market by End-Use Organization Type
  • Forecast by End-Use Organization Type (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • What This Means (Commercial Playbook)
  • Market-Math & Diffusion (Germany, End-Use Orgs)
• Germany - Market by AI Technology
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market-Math & Diffusion (Germany, AI Technology)
  • What This Means (Commercial Playbook)
• Germany - Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Germany, Pathway Stages)
  • What This Means (Commercial Playbook)
  • Signals to Watch (Germany)
  • Risks & Watch-outs

SECTION 10 - FRANCE

Market Overview & Dynamics

• Headline Math
• What's Driving France
• France - At a Glance
  • Key Numbers
  • 2032 Mix Snapshot
  • Where the Dollars Come From ('23->'32 Lift)
  • Three Takeaways
• Buyer & Hosting Posture (What RFPs Expect)
• Incidence & Screening - Context Signals (France)
• Policy, Reimbursement & Data-Residency (France-specific)
• Provider Landscape Snapshot (Route-to-market)
  • Anchor Systems & Networks
  • Local AI Ecosystem Touchpoints
• Packaging & Pricing Realities (France)
  • Packaging Snapshot
• Evidence & Regulatory Notes
• Competitive Lens (Indicative, Oncology-Relevant in FR)
• "So What" for France (GTM)

France - Market Estimates & Forecasts

• France - Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market-Math & Diffusion (France, Modality)
  • ho Contributes the Growth
  • What This Means (Commercial Playbook)
  • Competitive Lens (Indicative Clusters)
  • Signals to Watch (France-specific)
  • Risks & Watch-outs
• France - Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market-Math & Diffusion (France, Clinical Applications)
  • Who Contributes the Growth
  • What This Means (Commercial Playbook)
  • Competitive Lens (indicative clusters)
  • Signals to Watch (France)
  • Risks & Watch-outs
• France - Market by Tumor Site (2023-32)
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market-Math & Diffusion (France, Tumor Site)
  • What This Means (Commercial Playbook)
  • Signals to Watch
  • Risks & Watch-outs
• France - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market-Math & Diffusion (France, Revenue Streams)
  • Who Contributes the Growth
  • What This Means (Commercial Playbook)
  • Signals to Watch
  • Risks & Watch-outs
• France - Market by End-Use Organization Type
  • Forecast by End-Use Organization Type
  • Highlights
  • What's Shifting
  • What This Means (Commercial Playbook)
  • Market-Math & Diffusion (France, End-Use Orgs)
• France - Market by AI Technology
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market-Math & Diffusion (France, AI Technology)
  • Commercial Playbook (France)
• France - Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • What This Means (Commercial Playbook)
  • Market-Math & Diffusion (France, Pathway Stages)

SECTION 11 - UNITED KINGDOM

UK - Market Overview & Dynamics

• Headline Math
• What's Driving the UK
  • Demand & Supply Fundamentals
  • Screening Rails Moving Upstream
  • Adoption Enablers
• So What (Commercial Playbook)
• United Kingdom - At a Glance
  • Key Numbers (2023->2032)
  • Three Takeaways
  • Buyer & Hosting Posture (UK-specific)
  • GTM Cue
• Incidence & Screening - Quick Context
• Policy, Reimbursement & Governance Signals (UK-Specific)
• Provider Landscape Snapshot (Indicative, GTM-relevant)
• Packaging & Pricing Realities (UK)
• Evidence & Regulatory Notes (what buyers will ask)
• Signals to Watch ('25-'28)
• Competitive Lens (indicative, UK-relevant clusters)

UK - Market Estimates & Forecasts

• UK - Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (UK, Modality)
  • Who Contributes the Growth
  • What This Means (Commercial Playbook)
  • Signals to Watch (Execution)
  • Risks & Watch-outs
• UK - Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (UK, Clinical Applications)
  • Commercial Playbook
• UK - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (UK, Tumor Site)
• UK - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (UK, Revenue Streams)
  • Commercial Playbook (UK)
• UK - Market by End-Use Organization Type
• Forecast by End-Use Org Type (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (UK, End-Use Orgs)
• UK - Market by AI Technology
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (UK, AI Technology)
• UK - Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (UK, Pathway Stage)

SECTION 12 - ITALY

Italy - Market Overview and Dynamics

• Italy - Headline Math (2023->2032)
• What's Driving Italy (why the curve is steep)
• "So What" - Commercial Playbook (how to win)
• Italy - At a Glance
  • Key Numbers
  • Three Takeaways
  • Where the Growth Comes From (Dollar Lift 2023->2032)
  • Buyer & Hosting Posture (Italy)
  • Packaging & Pricing Cues
  • Risks & Watch-outs
  • What to Do Next (Italy)
• Incidence & Screening - Context Signals (Why Oncology AI Is a Priority)
• Policy, Reimbursement & Governance (what can accelerate/slow deals)
• Provider Landscape Snapshot (Indicative GTM Targets)
• Packaging & Pricing Realities (Italy-specific)
• Evidence & Regulatory Notes
• Signals to Watch (Next 12-24 months)

Italy - Market Estimates & Forecasts

• Italy - Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market-Math & Diffusion (Italy, Modality)
  • Commercial Playbook (Italy)
  • Risks & Watch-outs
• Italy - Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Italy, Clinical Applications)
• Italy - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Italy, Tumor Site)
  • Commercial Playbook (Tumor-site lens)
• Italy - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Italy, Revenue Streams)
• Italy - Market by End-Use Organization Type (2023-32)
  • Forecast by End-Use Organization Type (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (So-What)
  • Market Math & Diffusion (Italy, End-Use Orgs)
• Italy - Market by AI Technology
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (Italy, AI Technology)
• Italy - Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (So-What)
  • Market Math & Diffusion (Italy, Pathway Stage)

SECTION 13 - REST OF EUROPE

Market Overview and Analysis

• Headline Math (ROE)
• Regional Clusters & Indicative Split
• Rest of Europe (ROE) - At a Glance
  • Key Numbers (2023->2032)
  • Three Takeaways
  • Buyer & Hosting Posture (ROE)
  • GTM Cue
• What's Driving Each Cluster
  • Spain
  • BENELUX
  • Nordics
  • Eastern Europe
• Buyer Archetypes & Hosting Posture (by Cluster)
• Modality & Pathway Tilt
• Packaging & Pricing Guidance (ROE)
• Channel Strategy by Cluster
• "So What" for Execution
• Signals to Watch
• Risks & Watch-outs

ROE - Market Estimates & Forecasts

• ROE - Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Commercial Playbook
  • Market Math & Diffusion (ROE, Modality)
• Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (ROE, Clinical Application)
• ROE - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Commercial Playbook
  • Market-Math & Diffusion (ROE, Tumor Site)
• ROE - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Commercial Playbook
  • Market-Math & Diffusion (ROE, Revenue Stream)
• ROE - Market by End-Use Organization Type
  • Forecast by End-Use Organization Type (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Commercial Playbook
  • Market-Math & Diffusion (ROE, End-Use Orgs)
• Market by AI Technology
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Commercial Playbook
  • Market-Math & Diffusion (ROE, AI Technology)
• Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Commercial Playbook
  • Market-Math & Diffusion (ROE, Pathway Stage)

SECTION 14 - ASIA-PACIFIC (APAC)

APAC Market Overview and Dynamics

• Headlines
• What's Driving the Step-Up (Pan-Regional)
• Market Structure & Mix (What the Numbers Imply)
• Regulatory & Reimbursement Snapshot (Operator's View)
• Data Governance (Deployment Constraint & Design Choice)
• State Of Market Evolution (2025-2029 -> 2030-2032)
• Commercial Implications & Plays
• Risks & Watch-Outs (And How to Mitigate)
• What Good Looks Like (Operating Blueprint)

APAC - Market Estimates & Forecasts

• APAC - Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Headlines
  • What's Driving Growth (Beyond the Spreadsheets)
  • Modality Math (APAC Roll-Up; Rounded)
  • Where the Dollars Arise (Illustrative 2032 Splits by Modality)
  • Regulatory & Market-Access Cues to Watch
  • Commercial Implications
• APAC - Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Headlines
  • Regional Synthesis
  • APAC Totals by Clinical Application (Rolled-Up; Rounded)
  • Who Drives Each Application? (2032 Revenue Split Within Application)
  • Commercial Implications
• APAC - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Headlines
  • Regional Synthesis
  • Who Leads by Country/Site (2032)
  • Commercial Implications
• APAC - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Headlines
  • Where the Dollar-Lift Comes From (2023->2032)
  • Country Composition
  • Commercial Cues
• APAC - Market by End-Use Organization Type
  • Forecast by End-Use Org Type (USD Mill, 2023-32)
  • Headlines
  • Regional Synthesis
  • Source: Marketstrat Estimates & Forecast Model
  • Who Buys Which Category (2032 Split Inside Each End-Use)
  • Commercial Implications
  • APAC Totals by End-Use Org (Rolled-Up; Rounded)
• APAC - Market by AI Technology
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Headlines
  • Regional Synthesis
  • APAC Totals by AI Technology (Rolled-Up; Rounded)
  • Commercial Implications
• APAC - Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Headlines
  • Regional Synthesis
  • Country / Sub-Region Pattern is Strikingly Uniform
  • Market Math (Rounded, APAC Totals)
  • Commercial Implications

SECTION 15 - CHINA

Market Overview and Analysis

• Headline Math (China)
• China - At a Glance (Key Numbers, 2023->2032)
• What's Driving China
  • Demand & Supply Fundamentals
  • Screening Rails (Moving Upstream)
  • Adoption Enablers
• Buyer & Hosting Posture (China-Specific)
• Commercial Playbook - How to Win
• Key Takeaways (China)
• Incidence & Screening - Quick Context (for planning; directional)
• Provider Landscape Snapshot (indicative, GTM-relevant)
• Packaging & Pricing Realities (China)
• Signals to Watch ('25-'28)

China - Market Estimates & Forecasts

• China - Market by Modality (2023-32)
  • Forecast by Modality (USD Mill, 2023-32)
  • Highlights (2023->2032)
  • What's Shifting (Local Market Mechanics)
  • Pricing & Packaging Posture (by Modality)
  • Who Drives the Growth
  • Competitive Lens
  • Signals to Watch
  • Risks
  • Actions (90-day Playbook)
  • Market Math & Diffusion (China, Modality)
• China - Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (Local Mechanics)
  • Market Math & Diffusion (China, Clinical Application)
  • Who Drives the Growth
  • Pricing & Packaging (by Application)
  • Competitive Lens
  • Signals to Watch
  • Risks
  • Actions (90-day Playbook)
• China - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (China, Tumor Site)
  • Who Drives the Growth
  • Pricing & Packaging
  • Competitive Lens
  • Signals to Watch
  • Actions - 90-Day Playbook
• China - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (China, Revenue Stream)
  • Who Drives the Growth
  • Pricing & Packaging
  • Competitive Lens
  • Signals to Watch
  • Actions - 90-Day Playbook
• China - Market by End-Use Organization Type
  • Forecast by End-Use Organization Type (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Market Math & Diffusion (China, End-Use Orgs)
  • Who Drives the Growth
  • Pricing & Packaging
  • Competitive Lens
  • Signals to Watch
  • Risks
  • Actions - 90-Day Playbook
• China - Market by AI Technology (2023-32)
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth
  • Market Math & Diffusion (China, AI Technology)
  • Pricing & Packaging
  • Competitive Lens
  • Signals to Watch
  • Risks
  • Actions - 90-Day Playbook
• China - Market by Pathway Stage (2023-32)
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth
  • Market Math & Diffusion (China, Pathway Stage)
  • Pricing & Packaging
  • Competitive Lens
  • Signals to Watch
  • Risks
  • Actions - 90-Day Playbook

SECTION 16 - JAPAN

Market Overview and Analysis

• Headline Math
• Japan - At a Glance
• What's Driving Japan
  • Demand & Supply Fundamentals
  • Screening Rails (Upstream Engines)
  • Adoption Enablers
• Buyer & Hosting Posture (Japan)
• Commercial Playbook - How to Win
• Key Takeaways (Japan)
• Incidence & Screening - Quick Context (Planning Cues)
  • Signals to Watch ('25-'28)
  • Risks

Market Estimates & Forecasts

• Japan - Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth
  • Pricing & Packaging
  • Market Math & Diffusion (Japan, Modality)
  • Competitive Lens
  • Signals to Watch
  • Risks
  • Actions (90-day playbook)
• Japan - Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth
  • Market Math & Diffusion (Japan, Clinical Application)
  • Pricing & Packaging
  • Competitive Lens
  • Signals to Watch
  • Actions (90-day Playbook)
• Japan - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth
  • Market Math & Diffusion (Japan, Tumor Site)
  • Pricing & Packaging
  • Competitive Lens
  • Signals to Watch
  • Risks
  • Actions (90-day Playbook)
• Japan - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth
  • Market Math & Diffusion (Japan, Revenue Stream)
  • Pricing & Packaging
  • Actions (90-day Playbook)
• Japan - Market by End-Use Organization Type
  • Forecast by End-Use Organization Type (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth
  • Market Math & Diffusion (Japan, End-Use Orgs)
  • Pricing & Packaging
  • Competitive Lens
  • Signals to Watch
  • Actions (90-day Playbook)
• Japan - Market by AI Technology
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth
  • Market Math & Diffusion (Japan, AI Technology)
  • Pricing & Packaging
  • Actions (90-day Playbook)
• Japan - Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth
  • Market Math & Diffusion (Japan, Pathway Stage)
  • Pricing & Packaging
  • Actions (90-day Playbook)

SECTION 17 - INDIA

Market Overview & Dynamics

• Headline Math (India, 2023->2032)
• What's Driving India
  • Demand & Supply Fundamentals
  • Adoption Enablers & Guardrails
  • Buyer & Hosting Posture (India-specific)
  • Commercial Playbook (How to Win)
  • India - At a Glance (Key Numbers, 2023->2032)
  • Three Takeaways
  • Incidence & Screening - Quick Context (for GTM framing)
  • Competitive Lens (indicative, India-relevant Clusters)
  • Packaging & Pricing Realities (India)

Market Estimates & Forecasts

• India - Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Highlights
  • What's shifting (India-specific)
  • Who Drives the Growth
  • Market Math & Diffusion (India, Modality)
  • Pricing & Packaging (to win in India)
  • Competitive Lens
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Actions (Playbook)
• India - Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (India-specific)
  • Who Drives the Growth
  • Market Math & Diffusion (India, Clinical Application)
  • Pricing & Packaging (to win in India)
  • Signals to watch ('25-'28)
  • Risks
  • 90-day Playbook
• India - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (India-specific)
  • Who Drives the Growth
  • Market Math & Diffusion (India, Clinical Application)
  • Pricing & Packaging (to win in India)
  • Signals to watch ('25-'28)
  • Risks
  • 90-day Playbook
  • Incidence & Screening - Quick Context (India)
  • Estimated New Cases (2022)
  • Programmatic Screening Rails
• India - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (India-specific)
  • Who Drives the Growth
  • Market Math & Diffusion
  • Pricing & packaging (to win in India)
  • Signals to watch ('25-'28)
  • Risks
  • 90-day Playbook
• India - Market by End-Use Organization Type
  • Forecast by End-Use Org Type (USD Mill, 2023-32)
  • Highlights
  • What's shifting (India-specific)
  • Who Drives the Growth
  • Market Math & Diffusion (India, End-Use Orgs)
  • Pricing & Packaging (to win in India)
  • Signals to Watch ('25-'28)
  • 90-day Playbook
• India - Market by AI Technology
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (India-Specific)
  • Who Drives the Growth
  • Market Math & Diffusion (India, AI Technology)
  • Pricing & Packaging (to win in India)
  • Signals to watch ('25-'28)
  • 90-day Playbook
• India - Market by Pathway Stage - Japan
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (India-specific)
  • Who Drives the Growth
  • Market Math & Diffusion (India, Pathway Stage)
  • Pricing & packaging (to win in India)
  • Signals to watch ('25-'28)
  • 90-day Playbook

SECTION 18 - REST OF ASIA-PACIFIC (ROAPAC)

Market Overview and Analysis

• Headline Math (ROAPAC)
• ROAPAC Clusters (Definitions + Countries)
• What's Driving ROAPAC
  • Demand & Supply Fundamentals
  • Adoption Enablers
• Commercial Playbook (How to Win)
• Pricing & Packaging Truths
• Buyer & Hosting Posture (by Cluster)
• Incidence & Screening - Quick Context Signals
• ROAPAC - At-a-Glance (Key Numbers, 2023->2032)
• Three Takeaways
• Packaging & Pricing Realities
• Evidence, Regulatory & Governance Notes
• Signals to Watch ('25-'28)
• Competitive Lens (Indicative Clusters)

Market Estimates & Forecasts

• ROAPAC - Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (by Cluster)
  • Who Drives the Growth ('23->'32)
  • Market Math & Diffusion (ROAPAC, Modality)
  • So-What (Pricing & Packaging)
  • Competitive Lens (Indicative Clusters)
  • Signals to Watch ('25-'28)
  • Risks
• ROAPAC - Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (by Cluster)
  • Who Drives the Growth
  • Market Math & Diffusion (ROAPAC, Clinical Application)
  • So-What (Pricing/Packaging)
  • Signals to Watch ('25-'28)
  • Risks
• ROAPAC - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (by Cluster)
  • Market Math & Diffusion (ROAPAC, Tumor Site)
  • Pricing/Packaging
  • Signals to Watch ('25-'28)
  • Risks
  • 90-day Playbook
• ROAPAC - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (by Cluster)
  • Who Drives the Growth
  • Market Math & Diffusion (ROAPAC, Revenue Stream)
  • So-What (Pricing/Packaging)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-day Playbook
• ROAPAC - Market by End-Use Organization Type
  • Forecast by End-Use Organization Type (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (by Cluster)
  • Who Drives the Growth
  • Market Math & Diffusion (ROAPAC, End-Use Org)
  • Pricing & Packaging (to win)
  • Signals to watch ('25-'28)
  • Risks
  • 90-day Playbook
• ROAPAC - Market by AI Technology
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Market Math & Diffusion (ROAPAC, AI Technology)
  • Who Drives the Growth ('23->'32)
  • What's Shifting (by Cluster)
  • Pricing & Packaging (to win)
  • Signals to watch ('25-'28)
  • Risks
  • 90-day Playbook
• ROAPAC - Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (by Cluster)
  • Who Drives the Growth ('23->'32)
  • Market Math & Diffusion (ROAPAC, Pathway Stage)
  • Pricing & Packaging (to win)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-day Playbook

SECTION 19 - LATIN AMERICA (LATAM)

Market Overview and Dynamics

• Headline Math
• What's Driving LATAM (Demand & Supply Fundamentals)
• Cluster Lens (Who Buys, How to Win)
• Buyer & Hosting Posture
• Incidence & Screening - Quick Context (Operational Impact)
• Packaging & Pricing Realities
• Evidence & Regulatory Notes (What Buyers will Ask)
• Competitive Lens (Indicative, LATAM-relevant Clusters)
• LATAM - At-a-Glance (Key Numbers, 2023->2032)
• Three Takeaways
• 90-Day Commercial Playbook (Action)

Market Estimates & Forecasts

• LATAM - Market by Modality
  • Forecast by Modality (USD Mill, 2023-32)
  • Clusters (Definitions & GTM Posture)
  • Highlights
  • What's Shifting (by Cluster)
  • Who Drives the Growth
  • Market Math & Diffusion (LATAM, Modality)
  • Pricing & Packaging (To Win)
  • Competitive Lens (Indicative)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-day Playbook
• LATAM - Market by Clinical Application
  • Forecast by Clinical Application (USD Mill, 2023-32)
  • Clusters (Definitions & GTM Posture)
  • Highlights
  • Who Drives the Growth ('23->'32 Contribution)
  • Market Math & Diffusion (LATAM, Clinical Application)
  • Pricing & Packaging (to win)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Playbook
• LATAM - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Clusters (How to Interpret The Tumor Mix)
  • Highlights
  • Who Drives the Growth ('23->'32)
  • Market Math & Diffusion (LATAM, Tumor Site)
  • Pricing & Packaging (to Win)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Playbook
• LATAM - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Clusters (Definitions & GTM Posture)
  • Highlights
  • Who Drives the Growth ('23->'32 Contribution)
  • Market Math & Diffusion (LATAM, Revenue Stream)
  • Pricing & Packaging (to win)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Playbook
• LATAM - Market by End-Use Organization Type
  • Forecast by End-Use Organization Type (USD Mill, 2023-32)
  • Clusters (Operating Reality & GTM)
  • Highlights
  • Who Drives the Growth ('23->'32)
  • Market Math & Diffusion (LATAM, End-Use Org)
  • Pricing & Packaging (to win)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Playbook
• LATAM - Market by AI Technology
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Clusters (Operating Reality & GTM)
  • Highlights
  • Who Drives the Growth ('23->'32 Contribution)
  • Market Math & Diffusion (LATAM, AI Technology)
  • Pricing & Packaging (to win)
  • Competitive Lens (Indicative)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Playbook
• LATAM - Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting (mix)
  • Who Drives the Growth ('23->'32)
  • Market Math & Diffusion (LATAM, Pathway Stage)
  • Pricing & Packaging (to win)
  • Cluster Lens (Practical GTM)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Playbook

SECTION 20 - MIDDLE EAST & AFRICA (MEA)

Market Overview and Dynamics

• Headline Math
• What's Driving MEA (Demand & Supply Fundamentals)
  • Disease & Activity
  • Capacity & Workforce Reality
  • Screening Rails (High-Signal)
  • Adoption Enablers
• Commercial Playbook by Custer (How To Win)
• MEA - At a Glance
• Buyer & Hosting Posture (What Procurement asks for)
• Incidence & Screening - Quick Context Cues (for GTM Planning)
• Packaging & Pricing Realities
• Evidence & Regulatory Notes
• Signals to Watch ('25-'28)
• Three Takeaways
• MEA - At-a-Glance Card

Market Estimates & Forecasts

• Market by Modality (2023-32)
  • Forecast by Modality (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth
  • Market Math & Diffusion (MEA, Modality)
  • Pricing & Packaging - Actionable Posture by Cluster
  • Competitive Lens (Indicative)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day GTM Playbook
• Market by Clinical Application
  • Forecast by Clinical Application (USD Mil, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth ('23->'32)
  • Market Math & Diffusion (MEA, Clinical Application)
  • So-What (Pricing/Packaging)
  • Competitive Lens (Indicative)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Playbook
• MEA - Market by Tumor Site
  • Forecast by Tumor Site (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth ('23->'32)
  • Market Math & Diffusion (MEA, Tumor Site)
  • Pricing & Packaging (to win)
  • Incidence & Screening - Quick Context (operational cues)
  • Competitive Lens (Indicative)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Playbook
• MEA - Market by Revenue Stream
  • Forecast by Revenue Stream (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth ('23->'32)
  • Market Math & Diffusion (MEA, Revenue Stream)
  • Pricing & Packaging (how to win)
  • Competitive Lens (indicative)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Playbook
• MEA - Market by End-Use Organization Type
  • Forecast by End-Use Organization Type (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth ('23->'32)
  • Market Math & Diffusion (MEA, End-Use Org Type)
  • Pricing & Packaging (how to win)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Playbook
• MEA - Market by AI Technology
  • Forecast by AI Technology (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth ('23->'32)
  • Market Math & Diffusion (MEA, AI Technology)
  • Pricing & Packaging (how to win)
  • Competitive Lens (indicative)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Playbook
• MEA - Market by Pathway Stage
  • Forecast by Pathway Stage (USD Mill, 2023-32)
  • Highlights
  • What's Shifting
  • Who Drives the Growth ('23->'32)
  • Market Math & Diffusion (MEA, Pathway Stage)
  • Pricing & Packaging (how to win)
  • Competitive Lens (indicative)
  • Signals to Watch ('25-'28)
  • Risks
  • 90-Day Playbook

List of Tables

• Table 1: World Market for AI in Oncology Imaging by Region (2023-2032, USD Million)
• Table 2: World Market for Oncology Imaging AI by Country x End-Use Org (2023)
• Table 3: World Market for Oncology Imaging AI by Country x End-Use Org (2032)
• Table 4: World Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 5: World Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 6: World Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 7: World Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 8: World Market for Oncology Imaging AI by End-Use Org (USD Mill, 2023-32)
• Table 9: World Market for Oncology Imaging AI by Technology (USD Mill, 2023-32)
• Table 10: World Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 11: World Market for Oncology Imaging AI by Region x Modality (USD Mill, 2023)
• Table 12: World Market for Oncology Imaging AI by Region x Modality (USD Mill, 2032)
• Table 13: World Market for Oncology Imaging AI by Region x Revenue Stream (USD Mill, 2023)
• Table 14: World Market for Oncology Imaging AI by Region x Revenue Stream (USD Mill, 2032)
• Table 15: World Market for Oncology Imaging AI by Region x Clinical Application (USD Mill, 2023)
• Table 16: World Market for Oncology Imaging AI by Region x Clinical Application (USD Mill, 2032)
• Table 17: World Market for Oncology Imaging AI by Tumor Site x Modality (USD Mill, 2023)
• Table 18: World Market for Oncology Imaging AI by Tumor Site x Modality (USD Mill, 2032)
• Table 19: World Market for Oncology Imaging AI by Tumor Site x Clinical Application (USD Mill, 2023)
• Table 20: World Market for Oncology Imaging AI by Tumor Site x Clinical Application (USD Mill, 2032)
• Table 21: World Market for Oncology Imaging AI by Tumor Site x Revenue Stream (USD Mill, 2023)
• Table 22: World Market for Oncology Imaging AI by Tumor Site x Revenue Stream (USD Mill, 2032)
• Table 23: World Market for Oncology Imaging AI by Modality x Revenue Stream (2023)
• Table 24: World Market for Oncology Imaging AI by Modality X Revenue Stream (2032)
• Table 25: World Market for Oncology Imaging AI by Clinical Application x Revenue Stream (2023)
• Table 26: World Market for Oncology Imaging AI by Clinical Application x Revenue Stream (2032)
• Table 27: World Market for Oncology Imaging AI - By Pathway Stage X Revenue Stream (USD Mill, 2023)
• Table 28: World Market for Oncology Imaging AI - By Pathway Stage X Revenue Stream (USD Mill, 2032)
• Table 29: World Market for Oncology Imaging AI - By Pathway Stage X Modality (USD Mill, 2023)
• Table 30: World Market for Oncology Imaging AI - By Pathway Stage X Modality (USD Mill, 2032)
• Table 31: World Market for Oncology Imaging AI by Pathway Stage x Clinical Application (USD Mill, 2023)
• Table 32: World Market for Oncology Imaging AI by Pathway Stage x Clinical Application (USD Mill, 2032)
• Table 33: World Market for Oncology Imaging AI by Pathway Stage x End-use Org (USD Mill, 2023)
• Table 34: World Market for Oncology Imaging AI by Pathway Stage x End-use Org (USD Mill, 2032)
• Table 35: World Market for Oncology Imaging AI by Pathway Stage x AI Technology (USD Mill, 2023)
• Table 36: World Market for Oncology Imaging AI by Pathway Stage x AI Technology (USD Mill, 2032)
• Table 37: North American Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 38: North American Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 39: North American Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 40: North American Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 41: North American Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 42: North American Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 43: North America Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 44: United States Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 45: United States Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 46: United States Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 47: United States Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 48: United States Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 49: United States Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 50: United States Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 51: Canadian Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 52: Canadian Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 53: Canadian Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 54: Canadian Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 55: Canadian Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 56: Canadian Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 57: Canadian Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 58: European Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 59: European Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 60: European Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 61: European Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 62: European Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 63: European Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 64: European Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 65: German Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 66: German Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 67: German Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 68: German Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 69: German Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 70: German Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 71: German Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 72: French Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 73: French Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 74: French Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 75: French Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 76: French Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 77: French Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 78: French Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 79: UK Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 80: UK Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 81: UK Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 82: UK Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 83: UK Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 84: UK Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 85: UK Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 86: Italian Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 87: Italian Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 88: Italian Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 89: Italian Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 90: Italian Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 91: Italian Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 92: Italian Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 93: Rest of European (ROE) Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 94: Rest of European (ROE) Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 95: Rest of European (ROE) Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32).
• Table 96: Rest of European (ROE) Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 97: Rest of European (ROE) Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 98: Rest of European (ROE) Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 99: Rest of European (ROE) Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 100: APAC Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 101: APAC Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 102: APAC Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 103: APAC Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 104: APAC Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 105 APAC Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 106: Chinese Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 107: Chinese Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 108: Chinese Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 109: Chinese Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 110: Chinese Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 111: Chinese Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 112: Chinese Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 113: Japanese Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 114: Japanese Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 115: Japanese Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 116: Japanese Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 117: Japanese Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 118: Japanese Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 119: Japanese Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 120: Indian Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 121: Indian Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 122: Indian Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 123: Indian Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 124: Indian Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 125: Indian Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 126: Indian Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 127: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 128: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 129: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 130: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 131: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 132: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 133: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 134: LATAM Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
• Table 135: MEA Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Table 136: MEA Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Table 137: MEA Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Table 138: MEA Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Table 139: MEA Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Table 140: MEA Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Table 141: MEA Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)

List of Figures

• Figure 1: World Oncology Imaging AI Market by Pathway Stage - 2023 vs 2032
• Figure 2: Oncology Imaging AI - Global Drivers & Restraints
• Figure 3: Oncology Imaging AI Market by Region - 2032 Revenue and 2023-2032 CAGR
• Figure 4: Oncology Imaging AI Market by Modality - 2023 vs 2032
• Figure 5: Oncology Imaging AI Market by Clinical Application - 2023 vs 2032
• Figure 6: Oncology Imaging AI - Competitive Cluster Architecture
• Figure 7: Oncology Imaging AI - Markintel Segmentation Compass (Full Taxonomy)
• Figure 8: Oncology Imaging AI - Dual-Lens Forecast Build
• Figure 9: Oncology Imaging AI - From Signals to Strategy
• Figure 10: Markintel M3 - Market Momentum Matrix (AI Software Key Sub-Segments)
• Figure 11: Markintel ARC Grid - AI Software - Oncology Imaging AI
• Figure 12: Markintel GTM Growth vs. Maturity Matrix - AI Software Vendors (Oncology Imaging AI)
• Figure 13: Upgrade & Package Ladder - AI Software - Oncology Imaging AI
• Figure 14: Markintel M3 - Market Momentum Matrix (Imaging OEMs)
• Figure 15: Markintel ARC Grid - Imaging OEMs - Oncology Imaging AI
• Figure 16: Markintel GTM Growth vs. Maturity Matrix - Imaging OEM Vendors (Oncology Imaging AI)
• Figure 17: Upgrade & Package Ladder - Imaging OEM Cluster - Oncology Imaging AI
• Figure 18: Markintel M3 - Market Momentum Matrix - RT/Oncology Planning (Oncology Imaging AI)
• Figure 19: Markintel ARC Grid - RT/Oncology Planning - Oncology Imaging AI
• Figure 20: Markintel GTM Growth vs. Maturity Matrix - RT/Oncology Planning (Oncology Imaging AI)
• Figure 21: Upgrade & Package Ladder - RT/Oncology Planning Cluster - Oncology Imaging AI
• Figure 22: Markintel M3 - Market Momentum Matrix (AI Platform & Cloud Sub-segment)
• Figure 23: Markintel ARC Grid - AI Platforms & Cloud - Oncology Imaging AI
• Figure 24: Markintel GTM Growth vs. Maturity Matrix - AI Platforms and Cloud (Oncology Imaging AI)
• Figure 25: Upgrade & Package Ladder - AI Platforms & Cloud - Oncology Imaging AI
• Figure 26: Markintel M3 - Market Momentum Matrix (AI Providers & Teleradiology Sub-Segment)
• Figure 27: Markintel ARC Grid - Providers & Teleradiology - Oncology Imaging AI
• Figure 28: Markintel GTM Growth vs. Maturity Matrix - Providers & Teleradiology (Oncology Imaging AI)
• Figure 29: Upgrade & Package Ladder - Providers & Teleradiology Cluster - Oncology Imaging AI
• Figure 30: Markintel M3 - Market Momentum Matrix (Imaging-Pharma/CRO & Trials Key Sub-Segment)
• Figure 31: Markintel ARC Grid - Imaging-Pharma / CRO & Trials - Oncology Imaging AI
• Figure 32: Markintel GTM Growth vs. Maturity Matrix - Imaging-Pharma / CRO & Trials (Oncology Imaging AI)
• Figure 33: Upgrade & Package Ladder - Imaging-Pharma / CRO & Trials - Oncology Imaging AI
• Figure 34: Global Oncology Imaging AI - Country x End-Use Org (2032 Market Size and Index vs. Global Mix)
• Figure 35: Global Oncology Imaging AI - Country x End-Use (Dollar Lift 2023 to 2032)
• Figure 36: Global Oncology Imaging AI Market by Modality: 2023 vs. 2032
• Figure 37: Global Oncology Imaging AI Growth Contribution by Modality: Dollar Lift 2023 to 2032
• Figure 38: Global Oncology Imaging AI Market by Clinical Application: 2023 vs. 2032
• Figure 39: Global Oncology Imaging AI Growth Contribution by Clinical Application: Dollar Lift 2023 to 2032
• Figure 40: Global Oncology Imaging AI Growth Contribution by Tumor Site: Dollar Lift 2023 to 2032
• Figure 41: Global Oncology Imaging AI Growth Contribution by Tumor Site: Dollar Lift 2023 to 2032
• Figure 42: Global Oncology Imaging Growth Contribution by Revenue Stream: Dollar Lift 2023 to 2032
• Figure 43: Global Oncology Imaging Market by End-Use Org: 2023 vs. 2032
• Figure 44: Global Oncology Imaging Growth Contribution by End-Use Org: Dollar Lift 2023 to 2032
• Figure 45: Global Oncology Imaging Market by AI Technology: 2023 vs. 2032
• Figure 46: World Market for Oncology Imaging AI by Technology (USD Mill, 2023-32)
• Figure 47: Global Oncology Imaging Market by Pathway Stage: 2023 vs. 2032
• Figure 48: Global Oncology Imaging AI Growth Contribution by Pathway Stage: Dollar Lift 2023 to 2032
• Figure 49: Global Oncology Imaging AI - Region x Modality (2032 Market Size and Index vs. Global Mix)
• Figure 50: Global Oncology Imaging AI - Region x Modality (Dollar Lift 2023 vs 2032)
• Figure 51: Global Oncology Imaging AI - Region x Revenue Stream (2032 Market Size and Index vs. Global Mix)
• Figure 52: Global Oncology Imaging AI - Region x Revenue Stream (Dollar Lift 2023 to 2032)
• Figure 53: World Market for Oncology Imaging AI by Region x Clinical Application (USD Mill, 2032)
• Figure 54: Global Oncology Imaging AI - Region x Clinical Application (Dollar Lift 2023 to 2032)
• Figure 55: Global Oncology Imaging AI - Tumor Site x Modality (2032 Market Size and Index vs. Global Mix)
• Figure 56: Global Oncology Imaging AI - Tumor Site x Modality (Dollar Lift 2023 to 2032)
• Figure 57: Global Oncology Imaging AI - Tumor Site x Clinical Application (2032 Market Size and Index vs. Global Mix)
• Figure 58: Global Oncology Imaging AI - Tumor Site x Clinical Application (Dollar Lift 2023 to 2032)
• Figure 59: Global Oncology Imaging AI - Tumor Site x Revenue Stream (2032 Market Size and Index vs. Global Mix)
• Figure 60: Global Oncology Imaging AI - Tumor Site x Revenue Stream (Dollar Lift 2023 to 2032)
• Figure 61: Global Oncology Imaging AI - Modality x Revenue Stream (2032 Market Size and Index vs. Global Mix)
• Figure 62: Global Oncology Imaging AI - Modality x Revenue Stream (Dollar Lift 2023 to 2032)
• Figure 63: Global Oncology Imaging AI - Clinical Application x Revenue Stream (2032 Market Size and Index vs. Global Mix)
• Figure 64: Global Oncology Imaging AI - Clinical Application x Revenue Stream (Dollar Lift 2023 to 2032)
• Figure 65: Global Oncology Imaging AI - Pathway Stage x Revenue Stream (2032 Market Size and Index vs. Global Mix)
• Figure 66: Global Oncology Imaging AI - Pathway Stage x Revenue Stream (Dollar Lift 2023 to 2032)
• Figure 67: Global Oncology Imaging AI - Pathway Stage x Modality (2032 Market Size and Index vs. Global Mix)
• Figure 68: Global Oncology Imaging AI - Pathway Stage x Modality (2032 Market Size and Index vs. Global Mix)
• Figure 69: Global Oncology Imaging AI - Pathway Stage x Clinical Application (2032 Market Size and Index vs. Global Mix)
• Figure 70: Global Oncology Imaging AI - Pathway Stage x Clinical Application (Dollar Lift 2023 to 2032)
• Figure 71: World Market for Oncology Imaging AI by Pathway Stage x End-use Org (2032 Market Size and Index vs. Global Mix)
• Figure 72: Global Oncology Imaging AI - Pathway Stage x End-Use (Dollar Lift 2023 to 2032)
• Figure 73: World Market for Oncology Imaging AI by Pathway Stage x AI Technology (2032 Over/Under Mix)
• Figure 74: World Market for Oncology Imaging AI by Pathway Stage x AI Technology (USD Mill, 2032)
• Figure 75: North America - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 76: North America - Modality Growth vs Scale (Bubble = Dollar Lift)
• Figure 77: North America - Country x Modality Dollar Lift, 2023 to 2032
• Figure 78: North America - Clinical Application Dollar-Lift, (2023-2032) [US$M]
• Figure 79: North America - Country x Clinical Application Dollar Lift, 2023 to 2032
• Figure 80: North America - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
• Figure 81: North America - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 82: North America - Country x Tumor Site Dollar Lift, 2023 to 2032
• Figure 83: North America - Tumor Site vs Scale (Bubble = Dollar Lift)
• Figure 84: North America - Revenue Streams Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 85: North America - Dollar Lift (from 2023 - 2032) by Revenue Stream (US vs Canada)
• Figure 86: North America - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
• Figure 87: North America - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 88: North America - Dollar Lift (from 2023 - 2032) by End-Use Org (US vs Canada)
• Figure 89: North America - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 90: North America - Dollar Lift (from 2023 - 2032) by AI Technology (US vs Canada)
• Figure 91: North America - Pathway Stages Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 92: North America - Dollar Lift (from 2023 - 2032) by Pathway Stage (US vs Canada)
• Figure 93: United States - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 94: United States - Modality Growth vs Scale (Bubble = Dollar Lift)
• Figure 95: United States - Modality Mix Shift (from 2023 to 2032) (Share Arrows)
• Figure 96: United States - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 97: United States - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
• Figure 98: United States - Clinical Application Shift (from 2023 to 2032) (Share Arrows)
• Figure 99: United States - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 100: United States - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
• Figure 101: United States - Tumor Site Mix Shift (from 2023 to 2032) (Share Arrows)
• Figure 102: United States - Revenue Streams Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 103: United States - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
• Figure 104: United States - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 105: United States - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
• Figure 106: United States - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 107: United States - AI technology Growth vs Scale (Bubble = Dollar Lift)
• Figure 108: United States - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 109: United States - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
• Figure 110: Canada - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 111: Canada - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
• Figure 112: Canada - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 113: Canada - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
• Figure 114: Canada - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 115: Canada - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 116: Canada - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 117: Canada - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 118: Canada - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
• Figure 119: Canada - End-Use Org Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 120: Canada - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 121: Canada - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 122: Canada - AI Technology Growth vs Scale (Bubble = Dollar Lift)
• Figure 123: Canada - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
• Figure 124: Canada - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 125: Canada - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 126: Europe - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 127: Europe - Dollar Lift '23-'32 by Modality (Stacked by Country)
• Figure 128: Europe - Modality Growth vs Scale (Bubble = Dollar Lift)
• Figure 129: Europe - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 130: Europe - Dollar Life '23-'32 by Clinical Application (Stacked by Country)
• Figure 131: Europe - Clinical Application - Growth vs Scale (Bubble = Dollar Lift)
• Figure 132: Europe - Tumor Sites Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 133: Europe - Dollar Life '23-'32 by Tumor Site (Stacked by Country)
• Figure 134: Europe - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
• Figure 135: Europe - Revenue Streams Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 136: Europe - Dollar Lift '23-'32 by Revenue Stream (Stacked by Country)
• Figure 137: Europe - Dollar-Lift Contribution, End-User Orgs, 2023 to 2032 (Waterfall)
• Figure 138: Europe - Dollar Lift '23-'32 by End-Use Org (Stacked by Country)
• Figure 139: Europe - AI technologies Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 140: Europe - Dollar Lift '23-'32 by AI Technology (Stacked by Country)
• Figure 141: Europe - Pathway Stages Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 142: Europe -Dollar Lift '23-'32 by Pathway Stage (Stacked by Country)
• Figure 143: Germany - Modality Slope (Oncology Imaging AI), 2023-2032
• Figure 144: Germany - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 145: Germany - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 146: Germany - Clinical Application Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 147: Germany - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
• Figure 148: Germany - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 149: Germany - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
• Figure 150: Germany - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 151: Germany - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 152: Germany - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 153: Germany - End-Use Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 154: Germany - End-Use Orgs Growth vs Scale (Bubble = Dollar Lift)
• Figure 155: Germany - End-Use Orgs Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 156: Germany - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 157: Germany - AI Technology Growth vs Scale (Bubble = Dollar Lift)
• Figure 158: Germany - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 159: Germany - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 160: Germany - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
• Figure 161: Germany - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 162: France - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 163: France - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 164: France - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
• Figure 165: France - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 166: France - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 167: France - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
• Figure 168: France - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 169: France - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 170: France - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 171: France - End-Use Orgs Growth vs Scale (Bubble = Dollar Lift)
• Figure 172: France - End-Use Orgs Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 173: France - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 174: France - AI Technology Growth vs Scale (Bubble = Dollar Lift)
• Figure 175: France - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 176: France - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 177: UK - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 178: UK - Modality Growth vs Scale (Bubble = Dollar Lift)
• Figure 179: UK - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 180: UK - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
• Figure 181: UK - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 182: UK - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
• Figure 183: UK - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 184: UK - Revenue Streams Site Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 185: UK - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 186:UK - End-Use Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 187: UK - End-Use Orgs Growth vs Scale (Bubble = Dollar Lift)
• Figure 188: UK - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 189: UK - AI Technology Growth vs Scale (Bubble = Dollar Lift)
• Figure 190: UK - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 191: UK - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 192: UK - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
• Figure 193: UK - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 194: Italy - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 195: Italy - Modality Growth vs Scale (Bubble = Dollar Lift)
• Figure 196: Italy - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 197: Italy - Clinical Applications Growth vs Scale (Bubble = Dollar Lift)
• Figure 198: Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 199: Italy - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 200: Italy - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 201: Italy - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
• Figure 202: Italy - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 203: Italy - End-use Orgs Growth vs Scale (Bubble = Dollar Lift)
• Figure 204: Italy - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 205: Italy - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 206: Italy - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 207: Italy - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
• Figure 208: Rest of Europe - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 209: Rest of Europe - Modality Growth vs Scale (Bubble = Dollar Lift)
• Figure 210: Rest of Europe - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 211: Growth vs Scale (Bubble = Dollar Lift)
• Figure 212: Rest of Europe - Clinical Application Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 213: Rest of Europe - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 214: Rest of Europe - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
• Figure 215: Rest of Europe - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 216: Rest of Europe - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 217: Rest of Europe - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 218: Rest of Europe - End-Use Orgs Growth vs Scale (Bubble = Dollar Lift)
• Figure 219: Rest of Europe - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 220: Rest of Europe - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 221: Rest of Europe - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 222: Rest of Europe - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 223: APAC - Modalities Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 224: APAC - Dollar Lift '23-'32 by Tumor Site (Stacked by Country)
• Figure 225: APAC - Clinical Applications Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 226: APAC - Dollar Lift '23-'32 by Clinical Application (Stacked by Country)
• Figure 227: APAC - Tumor Sites Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 228: APAC - Tumor Sites Dollar Lift '23-'32 by Tumor Site (Stacked by Country)
• Figure 229: APAC - Revenue Streams Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 230: APAC - Revenue Streams Dollar Lift '23-'32 by Tumor Site (Stacked by Country)
• Figure 231: APAC - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 232: End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 233: APAC - AI Technologies Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 234: APAC - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 235: APAC - Pathway Stages Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 236: APAC - Dollar Lift '23-'32 by Pathway Stage (Stacked by Country)
• Figure 237: China - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 238: China - Modality Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 239: China - Modality Growth vs Scale (Bubble = Dollar Lift)
• Figure 240: China - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 241: China - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
• Figure 242: China - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 243: China - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 244: China - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
• Figure 245: China - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 246: China - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 247: China - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 248: Growth vs Scale (Bubble = Dollar Lift)
• Figure 249: China - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 250: China - AI Technology Growth vs Scale (Bubble = Dollar Lift)
• Figure 251: China - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 252: China - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 253: China - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
• Figure 254: Japan - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 255: Japan - Modality Growth vs Scale (Bubble = Dollar Lift)
• Figure 256: Japan - Clinical Application Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 257: Japan - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
• Figure 258: Japan - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 259: Japan - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 260: Japan - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
• Figure 261: Japan - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 262: Japan - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
• Figure 263: Japan - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 264: Japan - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
• Figure 265: Japan - End-Use Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 266: Japan - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 267: Japan - End-Use Org Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 268: Japan - AI Technology Growth vs Scale (Bubble = Dollar Lift)
• Figure 269: Japan - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 270: Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 271: Japan - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
• Figure 272: India - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 273: India - Modality Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 274: India - Modality Growth vs Scale (Bubble = Dollar Lift)
• Figure 275: India - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 276: India - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
• Figure 277: India - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 278: India - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
• Figure 279: India - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 280: India - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 281: India - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 282: Growth vs Scale (Bubble = Dollar Lift)
• Figure 283: India - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 284: India - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
• Figure 285: India - AI Technology Growth vs Scale (Bubble = Dollar Lift)
• Figure 286: India - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 287: India - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
• Figure 288: ROAPAC - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 289: ROAPAC - Modality Growth vs Scale (Bubble = Dollar Lift)
• Figure 290: ROAPAC - Clinical Application Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 291: ROAPAC - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
• Figure 292: ROAPAC - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 293: ROAPAC - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 294: ROAPAC - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 295: ROAPAC - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
• Figure 296: ROAPAC - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
• Figure 297: ROAPAC - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 298: ROAPAC - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
• Figure 299: ROAPAC - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 300: ROAPAC - AI Technology Growth vs Scale (Bubble = Dollar Lift)
• Figure 301: ROAPAC - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 302: ROAPAC - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
• Figure 303: LATAM Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
• Figure 304: Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 305: LATAM - Modality Growth vs Scale (Bubble = Dollar Lift)
• Figure 306: LATAM Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
• Figure 307: LATAM - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 308: LATAM - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
• Figure 309: LATAM Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
• Figure 310: LATAM - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 311: LATAM - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
• Figure 312: LATAM Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
• Figure 313: LATAM - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 314: LATAM - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
• Figure 315: LATAM Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
• Figure 316: LATAM - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 317: Growth vs Scale (Bubble = Dollar Lift)
• Figure 318: LATAM Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
• Figure 319: LATAM - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 320: LATAM - AI Technology Growth vs Scale (Bubble = Dollar Lift)
• Figure 322: LATAM - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 323: Growth vs Scale (Bubble = Dollar Lift)
• Figure 325: MEA - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 326: MEA - Modality Growth vs Scale (Bubble = Dollar Lift)
• Figure 328: MEA - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 329: MEA - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
• Figure 331: MEA - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 332: MEA - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
• Figure 334: MEA - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 335: MEA - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
• Figure 337: MEA - End-Use Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 338: MEA - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
• Figure 340: MEA - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 341: MEA - AI Technology Growth vs Scale (Bubble = Dollar Lift)
• Figure 343: MEA - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
• Figure 344: MEA - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)